TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36639814

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical cystectomy (RARC) with intracorporeal ileal conduit diversion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC) with ileal conduit
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both RARC and ORC
Number of subjects: 50
Study: 36640127

Group type: EXPERIMENTAL
Intervention: MDNA55 (interleukin 4 receptor-targeting toxin) administered intratumorally as a single dose treatment (dose range of 18 to 240 μg) using convection-enhanced delivery (CED).
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-dose MDNA55 (>180 μg) in a subgroup of IL4R High and IL4R Low patients.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MDNA55 treatment in evaluable patients (n=32) based on mRANO criteria.
Number of subjects: 44
Study: 36640137

Group type: EXPERIMENTAL
Intervention: NHS-IL12 12 µg/kg SC q2w
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NHS-IL12 16.8 µg/kg SC q2w
Number of subjects: 13
Study: 36640164

Group type: EXPERIMENTAL
Intervention: Electronic urinary continence assessment system
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 36640430

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CRYO)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Radiofrequency (RF)
Number of subjects: 98
Study: 36640437

Group type: EXPERIMENTAL
Intervention: Realwear HMT-1 assisted reality device
Number of subjects: 139
Study: 36640582

Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium supplementation (1000 IU vitamin D)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vitamin D supplementation alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 36640725

Group type: EXPERIMENTAL
Intervention: 90 mg AVA treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30 mg AVA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36640790

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Right-sided hemicolectomy
Number of subjects: 278
Study: 36640794

Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab + immunosuppressant)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Infliximab withdrawal
Number of subjects: 207

Group type: COMPARATOR
Intervention: Immunosuppressant withdrawal
Number of subjects: 207
Study: 36640860

Group type: EXPERIMENTAL
Intervention: Alert notifying cardiologists at the time of patient visit
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Automated electronic message allowing review between visits
Number of subjects: 596

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 596
Study: 36640862

Group type: EXPERIMENTAL
Intervention: Commitment device (including daily bidirectional text messages, commitment contract, implementation intentions, support partner involvement)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Attention control (daily bidirectional text messages asking about adherence and weekly messages for weight and blood pressure)
Number of subjects: 37
Study: 36640965

Group type: EXPERIMENTAL
Intervention: Revascularization (when both FFR ≤ 0.80 and CFR < 2.0 were abnormal)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Medical treatment (for all others not undergoing revascularization)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Concordantly normal FFR/CFR
Number of subjects: 348
Study: 36641027

Group type: EXPERIMENTAL
Intervention: Dog treatment (DT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 128
Study: 36641093

Group type: EXPERIMENTAL
Intervention: Oleclumab 1500 mg (DL1) plus osimertinib 80 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oleclumab 3000 mg (DL2) plus osimertinib 80 mg
Number of subjects: 26
Study: 36641341

Group type: EXPERIMENTAL
Intervention: RSVPreF3/AS01
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 36641358

Group type: COMPARATOR
Intervention: Influenza vaccination (FV)
Number of subjects: 4307

Group type: COMPARATOR
Intervention: Pneumococcal vaccination (PV)
Number of subjects: 4307
Study: 36641457

Group type: EXPERIMENTAL
Intervention: Plain language recommendation (PLR) format
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard language version (original recommendation format)
Number of subjects: 240
Study: 36641605

Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale and MCI-Clinical Global Impression of Change (anchor measures)
Number of subjects: 769
Study: 36641607

Group type: COMPARATOR
Intervention: 80mg buntanetap QD in AD patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: 5mg, 10mg, 20mg, 40mg, 80mg buntanetap QD in PD patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo QD in AD patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo QD in PD patients
Number of subjects: 68
Study: 36641609

Group type: EXPERIMENTAL
Intervention: Free and Cued Selective Reminding Test (FCSRT)
Number of subjects: 2897

Group type: COMPARATOR
Intervention: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13)
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL)
Number of subjects: 2897
Study: 36641898

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Combination of lapatinib and trastuzumab
Number of subjects: 455

Group type: COMPARATOR
Intervention: pCR (pathological complete response)
Number of subjects: 455
Study: 36642080

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Lenalidomide alone
Number of subjects: 180
Study: 36642225

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting balloon (SEB) and provisional drug-eluting stent (DES)
Number of subjects: 3326

Group type: COMPARATOR
Intervention: Systematic drug-eluting stent (DES)
Number of subjects: 3326
Study: 36642226

Group type: EXPERIMENTAL
Intervention: Core digital engagement program (CDEP) via iPhone application and Apple Watch (Apple Watch Group)
Number of subjects: 26485

Group type: COMPARATOR
Intervention: Core digital engagement program (CDEP) alone (iPhone-only Group)
Number of subjects: 26485

Group type: EXPERIMENTAL
Intervention: Apple Watch Group
Number of subjects: 26485
Study: 36642232

Group type: EXPERIMENTAL
Intervention: TDM-guided voriconazole treatment
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard voriconazole dosing
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Composite primary endpoint (TDM group)
Number of subjects: 189
Study: 36642366

Group type: EXPERIMENTAL
Intervention: Resveratrol (250 mg/d escalated to 1,000 mg/d over 24 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resveratrol (combined with sirolimus)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sirolimus alone (control)
Number of subjects: 25
Study: 36642439

Group type: EXPERIMENTAL
Intervention: Guselkumab (GUS) 100 mg every 4 weeks (Q4W)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Guselkumab (GUS) 100 mg every 8 weeks (Q8W)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Combined GUS (Q4W + Q8W)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1554
Study: 36642509

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 36642608

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: lacto-ovo-vegetarian diet (VD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABCA1 transporter
Number of subjects: 30
Study: 36642667

Group type: EXPERIMENTAL
Intervention: THC (0.107 mg/kg, 8 mg for a 75-kg person)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: THC+CBD (0.107 mg/kg THC + 0.320 mg/kg CBD, 24 mg for a 75-kg person)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 47
Study: 36642931

Group type: EXPERIMENTAL
Intervention: NP10679, single or multiple doses
Number of subjects: 0
Study: 36643406

Group type: EXPERIMENTAL
Intervention: Abdominal palpation tests
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Posterior wall structure palpation (firm/soft)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Posterior wall bulging test (yes/no)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Abdominal resistance tests
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Palpation during scrotal invagination with Valsalva manoeuvre
Number of subjects: 44
Study: 36643597

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions with school-based health center (SBHC) primary care clinicians over two years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions
Number of subjects: 0
Study: 36643727

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia in T2D
Number of subjects: 46

Group type: COMPARATOR
Intervention: Insulin-induced hypoglycemia in controls
Number of subjects: 46
Study: 36643855

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination (two doses at 3-week intervals)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Home-isolated COVID-19 patients (control group)
Number of subjects: 100
Study: 36644169

Group type: EXPERIMENTAL
Intervention: MIPP-Kit PNX with resorbable bio-compatible glue
Number of subjects: 40
Study: 36644285

Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36644348

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: CNI-based regimen (Control)
Number of subjects: 0
Study: 36644504

Group type: EXPERIMENTAL
Intervention: Peak Systolic Velocity (PSV) in Common Carotid Artery (CCA)
Number of subjects: 8567

Group type: EXPERIMENTAL
Intervention: Peak Systolic Velocity (PSV) in Internal Carotid Artery (ICA)
Number of subjects: 8567
Study: 36644605

Group type: EXPERIMENTAL
Intervention: Screen-time reduction to ≤1 screen-hour daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no CVS diagnosis)
Number of subjects: 49
Study: 36644672

Group type: EXPERIMENTAL
Intervention: Culturally informed stress reduction intervention for Native American Head Start teachers
Number of subjects: 0
Study: 36644804

Group type: EXPERIMENTAL
Intervention: CTG + CAF
Number of subjects: 21

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 21
Study: 36644815

Group type: EXPERIMENTAL
Intervention: Thin facial bone (≤1 mm)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 42
Study: 36644853

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib mesylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib and regorafenib
Number of subjects: 0
Study: 36645051

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 45 mg once daily for 8 weeks (induction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg or 30 mg once daily for 52 weeks (maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36645168

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg BID) administered concurrent with chemotherapy
Number of subjects: 56
Study: 36645227

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention targeting physical weakness, cognitive impairment, malnutrition, and anemia
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study: 36645250

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 1295

Group type: COMPARATOR
Intervention: No remote ischaemic preconditioning (no RIPC)
Number of subjects: 1295
Study: 36645291

Group type: EXPERIMENTAL
Intervention: Low sodium intake (reduced salt intake)
Number of subjects: 313
Study: 36645446

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (daily telemedical rounds guided by eight German acute ICU care QIs)
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 1463

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 1463
Study: 36645499

Group type: EXPERIMENTAL
Intervention: Distress screeners (DT, PHQ-9, GAD-7)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: PHQ-9 and GAD-7
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Distress screeners
Number of subjects: 660
Study: 36645531

Group type: EXPERIMENTAL
Intervention: CVC-IN score ≥ 4
Number of subjects: 4707

Group type: COMPARATOR
Intervention: CVC-IN score < 4
Number of subjects: 4707

Group type: EXPERIMENTAL
Intervention: CVC-IN score
Number of subjects: 4707
Study: 36645699

Group type: EXPERIMENTAL
Intervention: Supportive Parenting App (SPA) intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 36645708

Group type: EXPERIMENTAL
Intervention: Tomando Control educational program delivered in a group format for 6 biweekly 1.5-hour sessions, led by either a community health worker or a diabetes nurse educator.
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Augmented version of Tomando Control or multifamily group treatment focused on problem-solving (for those who did not improve in the first phase).
Number of subjects: 330
Study: 36645792

Group type: EXPERIMENTAL
Intervention: Supplementary dolutegravir (50 mg) for 14 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both arms (supplementary dolutegravir and placebo)
Number of subjects: 130
Study: 36645791

Group type: EXPERIMENTAL
Intervention: HICs
Number of subjects: 12860

Group type: COMPARATOR
Intervention: LMICs
Number of subjects: 12860

Group type: COMPARATOR
Intervention: Mechanically ventilated children in LMICs
Number of subjects: 12860
Study: 36645885

Group type: EXPERIMENTAL
Intervention: COMP (dieting group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CTRL (nondieting group)
Number of subjects: 43
Study: 36645965

Group type: EXPERIMENTAL
Intervention: Combined optokinetic stimulation and cueing-assisted reading therapy (OKSREAD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control treatment (neuropsychological treatment not targeting visuospatial attention)
Number of subjects: 20
Study: 36645978

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 69
Study: 36646148

Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stents (LAMSs) with coaxial double-pigtail plastic stents (DPSs)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lumen-apposing metal stents (LAMSs) without coaxial double-pigtail plastic stents (DPSs)
Number of subjects: 67
Study: 36646196

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 27395

Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with aspirin
Number of subjects: 27395
Study: 36646210

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus carboplatin and pemetrexed
Number of subjects: 412

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 412
Study: 36646240

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections (7 monthly doses followed by PRN)
Number of subjects: 95
Study: 36646315

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 40 IU combined with COPE
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo combined with COPE
Number of subjects: 180
Study: 36646322

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 36646383

Group type: EXPERIMENTAL
Intervention: Zilver Vena venous stent
Number of subjects: 243
Study: 36646399

Group type: EXPERIMENTAL
Intervention: Favorite music
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Relaxing music (Unwind)
Number of subjects: 70

Group type: COMPARATOR
Intervention: White noise (control condition)
Number of subjects: 70
Study: 36646563

Group type: EXPERIMENTAL
Intervention: Self-consent
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Adult permission required
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Parental permission required
Number of subjects: 129
Study: 36646605

Group type: EXPERIMENTAL
Intervention: Monocyte to high-density lipoprotein cholesterol ratio (MHR)
Number of subjects: 2451

Group type: EXPERIMENTAL
Intervention: Quartile 4 (Q4) of MHR
Number of subjects: 2451
Study: 36646639

Group type: EXPERIMENTAL
Intervention: Manual breast pump
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 60
Study: 36646708

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF) initiation and duration
Number of subjects: 243

Group type: COMPARATOR
Intervention: Breastfeeding (BF)
Number of subjects: 243
Study: 36646800

Group type: EXPERIMENTAL
Intervention: non-invasive test
Number of subjects: 143
Study: 36646863

Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention for 8 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard healthcare (control)
Number of subjects: 0
Study: 36646862

Group type: EXPERIMENTAL
Intervention: Trainee only
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: Trainee with direct attending supervision
Number of subjects: 4347

Group type: COMPARATOR
Intervention: Attending only
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 4347
Study: 36646994

Group type: EXPERIMENTAL
Intervention: Stable average grip strength trajectory (n=85)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: High grip strength trajectory (n=27)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Change scores of weight-normalised grip strength
Number of subjects: 131

Group type: COMPARATOR
Intervention: Trajectory group membership
Number of subjects: 131
Study: 36647007

Group type: EXPERIMENTAL
Intervention: IPMN surveillance (imaging and laboratory tests every 6 to 12 months)
Number of subjects: 232
Study: 36647028

Group type: EXPERIMENTAL
Intervention: Sitting time ≥ 8 hours/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitting time < 8 hours/day
Number of subjects: 0
Study: 36647057

Group type: EXPERIMENTAL
Intervention: PEP device (5 cmH2O)
Number of subjects: 25
Study: 36647077

Group type: EXPERIMENTAL
Intervention: Setmelanotide treatment for 52 weeks
Number of subjects: 20
Study: 36647092

Group type: EXPERIMENTAL
Intervention: Clinic-based incentives
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Community-based smart lockers
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Home delivery
Number of subjects: 900

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 900
Study: 36647114

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study: 36647120

Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed therapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Post-operative physiological incoherence with increased preload dependency
Number of subjects: 73
Study: 36647177

Group type: EXPERIMENTAL
Intervention: Cognitive-motor exergames (trained five times a week in addition to conventional rehabilitation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard rehabilitation treatment only (control group)
Number of subjects: 40
Study: 36647213

Group type: EXPERIMENTAL
Intervention: HR-HPV positive women (n=231)
Number of subjects: 950

Group type: COMPARATOR
Intervention: HPV-negative women (n=573)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Any HPV positive women at mid-gestation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: HR-HPV positive women at mid-gestation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Overall outcomes for PTD, PPROM, PROM, and chorioamnionitis
Number of subjects: 950
Study: 36647478

Group type: EXPERIMENTAL
Intervention: Ensartinib (225 mg per day)
Number of subjects: 48
Study: 36647557

Group type: EXPERIMENTAL
Intervention: HealthScore intervention (six-month health coaching program with Fitbit and weekly coaching sessions)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HealthScore intervention
Number of subjects: 50
Study: 36647565

Group type: EXPERIMENTAL
Intervention: HSK3486 (0.4 mg kg -1 )
Number of subjects: 129

Group type: COMPARATOR
Intervention: Propofol (2.0 mg kg -1 )
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: HSK3486
Number of subjects: 129

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 129
Study: 36647599

Group type: EXPERIMENTAL
Intervention: Tumour-treating fields therapy
Number of subjects: 40
Study: 36647690

Group type: EXPERIMENTAL
Intervention: Bayesian approach for estimating treatment effect on recurrent events among subjects who would be alive regardless of treatment.
Number of subjects: 0
Study: 36647691

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 0
Study: 36647745

Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase activity (TKa) measured using DiviTum
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: New predefined cut-off for TKa
Number of subjects: 454